SAN DIEGO--(BUSINESS WIRE)--Illumina (NASDAQ:ILMN) today announced that important results from genotyping research in Crohn’s disease and Parkinson’s disease (PD) using Illumina’s Infinium® HumanHap300 BeadChip were published in peer-reviewed journals, Science and The Lancet.
